Filing Overview
This Form 8-K reports events involving Tivic Health Systems, Inc. on November 17, 2021, with the report signed November 18, 2021. The request metadata identifies Valion Bio, Inc., but the filing registrant is Tivic Health Systems, Inc. (Nasdaq: TIVC).
Material Agreement and Financial Position
- New headquarters: On November 17, 2021, the company entered into a sublease with Czarnowski Display Services, Inc. for approximately 9,091 square feet of office space in Hayward, California.
- Lease term: The sublease is expected to commence on or before November 26, 2021, and expires October 31, 2025.
- Rent: Beginning three months after commencement, monthly rent will be $12,272.87, plus the company’s pro rata share of operating costs, currently approximately $4,500 per month. The company is responsible for operating costs only during the first two months of that period.
- Escalation: Monthly rent increases 3.0% annually.
- IPO proceeds: The company previously sold 3,000,000 common shares at $5.00 per share, generating gross proceeds of $15.0 million.
- Over-allotment: The underwriter exercised its option for an additional 450,000 shares. The exercise closed November 18, 2021 and generated additional gross proceeds of $2.25 million.
- Total reported gross IPO proceeds: $17.25 million before underwriting discounts, commissions, and other offering expenses.
Changes Versus Prior Comparable Period
The filing does not provide comparative revenue, earnings, cash flow, margins, debt, liquidity, or balance-sheet data. The material changes disclosed are the execution of the new office sublease and the completion of the IPO over-allotment exercise.
Outlook, Risks, and Unusual Items
- The new sublease creates a multi-year occupancy commitment through October 2025, with annual rent increases and variable operating costs.
- The filing does not provide management guidance, operating forecasts, or a stated use of the IPO proceeds.
- The full sublease will be filed with the company’s Annual Report on Form 10-K for the year ended December 31, 2021; the filing’s summary does not provide all sublease terms.
- The Item 8.01 IPO information is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference except through specific reference.
Investor Verification Items
- Verify the registrant identity, because the supplied metadata names Valion Bio, Inc., while the filing names Tivic Health Systems, Inc.
- Review the complete sublease in the 2021 Form 10-K, including commencement, renewal, termination, insurance, maintenance, and default provisions.
- Confirm net IPO proceeds after underwriting discounts, commissions, and offering expenses.
- Review subsequent filings for the actual use of IPO proceeds and the company’s post-IPO liquidity.
- Confirm the final amount of operating costs and the timing of possession and rent commencement.